Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-04-07
1999-11-09
Celsa, Bennett
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 18, 4241841, 4241851, 530331, 530868, 2609982, A61K 3805, A61K 4505
Patent
active
059814918
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to a novel class of peptidyl derivatives, to processes for their preparation, and to their use in medicine.
BACKGROUND OF THE INVENTION
Tumour Necrosis Factor (TNF) is a cytokine which is produced initially as a cell-associated 28 kD precursor. It is released as an active, 17 kD form (D-M Jue et al, (1990) Biochemistry, 29:8371-8377), which can mediate a large number of deleterious effects in vivo. When administered to animals or humans it causes inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase responses, similar to those seen during acute infections and shock states. Chronic administration can also cause cachexia and anorexia. Accumulation of excessive TNF can be lethal.
There is considerable evidence from animal model studies that blocking the effects of TNF with specific antibodies can be beneficial in acute infections, shock states, graft versus host reactions and autoimmune disease. TNF is also an autocrine growth factor for some myelomas and lymphomas and can act to inhibit normal heamatopoiesis in patients with these tumours.
Preventing the production or action of TNF is, therefore, predicted to be a potent therapeutic strategy for many inflammatory, infectious, immunological or malignant diseases. These include, but are not restricted to, septic shock, haemodynamic shock and sepsis syndrome (Mathison et al, (1988) J. Clin. Invest. 81:1925-1937; Miethke et al (1992), J. Exp. Med. 175:91-98), post ischaemic reperfusion injury, malaria (Grau et al (1989), Immunol. Rev. 112:49-70); mycobacterial infection (Barnes et al (1992) Infect. Imm. 60:1441-6), meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, rheumatoid arthritis, multiple sclerosis, radiation damage, toxicity following administration of immunosuppressive monoclonal antibodies such as OKT3 or CAMPATH-1 and hyperoxic alveolar injury.
Current clinical anti-TNF strategies involve the use of corticosteroids such as dexamethasone, and the use of cyclosporin-A or FK506, which are non-specific inhibitors of cytokine gene transcription. Phosphodiesterase inhibitors such as pentoxyfilline have been shown to be more specific inhibitors of TNF gene transcription (Endres S . (1991) Immunol. 72:56-60, Schandene et al (1992), Immunol. 76:30-34, Alegre M L, et al (1991); Transplantation 52:674-679, Bianco et al (1991) Blood 78:1205-1221). Thalidomide has also been shown to inhibit TNF production by leucocytes (Sampajo et al (1991), J. Exp. Med. 173:699-703). In experimental settings, anti-TNF monoclonal antibodies, soluble TNF receptors and soluble TNF receptor/immunoadhesins have been shown to specifically inhibit the effects of TNF action (Bagby et al (1991) J. Infect. Dis. 163:83-88, Charpentier et al. (1991) Presse-med. 20:2009-2011, Silva et al (1990) J. Infect. Dis. 162:421-427; Franks et al (1991) Infect. Immun. 59:2609-2614, Tracey et al (1987) Nature 330:662-664; Fischer et al (1992) PNAS USA in press, Lesslauer et al (1991) Eur. J. Immunol. 21:2883-2886, Ashkenazi et al (1991) PNAS USA 88:10535-10539).
It has recently been shown that the effects of TNF are mediated by two peptides, TNF.alpha. and TNF.beta.. Although these peptides have only 30% homology with each other, they activate the same receptors and are encoded by immediately adjacent genes. As used herein, the term tumour necrosis factor or TNF therefore means tumour necrosis factor a and peptides having a high degrees of sequence homology with, or substantially similar physiological effects to, TNF.alpha., for example TNF.beta..
One of the objectives of the present invention is to provide compounds which substantially inhibit the release of TNF from cells, and therefore may be used in the treatment of conditions mediated by TNF. Such uses include, but are not limited to, the treatment of inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia and anorexia, acute infections, shock states,
REFERENCES:
Fournie-Zaluski et al., Eur. J. Biochem. 139 267-74 (1984).
Biochemsitry, vol. 29(33), pp. 7608-7617, 1990.
CA XP002014431 to Eur. J. Biochem., vol. 199(3), pp. 623-636, 1991.
CA XP002014432 to Biochem. Biophys. Res. Commun., vol. 120(2) pp. 686-691, 1984.
CA XP002014433 to JACS, vol. 116(11) pp. 5009-5010, 1994.
CA 122898, vol. 99, No. 15 to Farmaco, Ed Sci. vol. 38(6), pp. 391-396, 1983.
CA 152346, vol. 116, No. 15 to Asian J. Chem., vol. 4(1) pp. 144-151, Apr. 1992.
Baxter Andrew Douglas
Montana John
Owen David Alan
Celsa Bennett
Darwin Discovery Limited
LandOfFree
Peptidyl compounds and their therapeutic use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptidyl compounds and their therapeutic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidyl compounds and their therapeutic use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456011